LMF1
protein-codinglipase maturation factor 1
Gene summary
Involved in triglyceride metabolic process. Predicted to be active in endoplasmic reticulum membrane. Implicated in familial lipase maturation factor 1 deficiency. [provided by Alliance of Genome Resources, Jun 2026]
- C16orf26
- TMEM112
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~127.7 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0009527
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0009527
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0009527
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0009527
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0009527
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Endocrine; Gastrointestinal
Intervention: Cardiovascular; Endocrine; Gastrointestinal
Rationale: Individuals may present with severe hypertryglceridemia, with findings including gastrointestinal manifestations (abdominal pain, emesis, recurrent pancreatitis, hepatosplenomegaly), as well as eruptive xanthomata and lipemia retinalis, and dietary measures (fat restriction) and medical treatment (eg, gemfibrozil, omega-3 fatty acid supplementation) can be beneficial; Individuals may also manifest with diabetes mellitus, which can benefit from standard treatment (and which may also help with other manifestations)
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to LMF1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_022773.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 227 | 2 | 233 | ||
| missense | 4 | 322 | 49 | 4 | 379 | |
| nonsense | 5 | 13 | 1 | 19 | ||
| start loss | 0 | |||||
| frameshift | 6 | 7 | 13 | |||
| splice donor/acceptor (+/-2bp) | 1 | 3 | 3 | 7 | ||
| Total | 12 | 27 | 330 | 276 | 6 | 651 |
Highest pathogenic variant AF is 0.000060750102
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_073610.2 | 11 | MANE Select | |
| Ensembl | ENSP00000262301.12 | 11 | MANE Select | |
| RefSeq | NP_001338946.1 | 8 | Standard | |
| RefSeq | NP_001338947.1 | 9 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Transport of small molecules
- Assembly of active LPL and LIPC lipase complexes
- Plasma lipoprotein assembly, remodeling, and clearance
- Plasma lipoprotein remodeling
Biological Process
- triglyceride metabolic process
- endoplasmic reticulum to Golgi vesicle-mediated transport
- protein secretion
- protein glycosylation in Golgi
- chylomicron remnant clearance
Cellular Component
- endoplasmic reticulum membrane
- Golgi apparatus
- integral component of membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000262301
- Coding exons
- 11
- Length
- 127685
- Individuals with no LoFs
- 124553
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 113
- Defined
- 124666
- p
- 0.000453
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -1.79 | 446 | 351 | 1.27 | 0.0000225 | 3630 |
| Missense (PolyPhen) | 170 | 139.91 | 1.2151 | 1431 | ||
| Synonymous | -2.66 | 194 | 152 | 1.27 | 0.0000104 | 1140 |
| Loss of Function | 0.442 | 25 | 27.5 | 0.909 | 0.00000143 | 259 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00046 | 0.00045 | rare |
| Latino/Admixed American | 0.00044 | 0.00043 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00067 | 0.00067 | rare |
| Finnish | 0.00015 | 0.00014 | rare |
| European (Non-Finnish) | 0.00045 | 0.00044 | rare |
| South Asian | 0.00069 | 0.00069 | rare |
| Other | 0.00091 | 0.00083 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Involved in the maturation of specific proteins in the endoplasmic reticulum. Required for maturation and transport of active lipoprotein lipase (LPL) through the secretory pathway. Each LMF1 molecule chaperones 50 or more molecules of LPL. {ECO:0000250|UniProtKB:Q3U3R4, ECO:0000269|PubMed:24909692}.;
- Disease
- DISEASE: Combined lipase deficiency (CLD) [MIM:246650]: Characterized by repeated episodes of pancreatitis, tuberous xanthomas and lipodystrophy and is caused by deficiency of both lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL). {ECO:0000269|PubMed:17994020}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.118
Intolerance Scores
- LoFtool
- 0.865
- RVIS EVS
- 1.23
- RVIS percentile EVS
- 93.26
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.444
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |